---
document_datetime: 2025-11-23 08:09:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva-pharma-bv.html
document_name: ribavirin-teva-pharma-bv.html
version: success
processing_time: 0.1102258
conversion_datetime: 2025-12-28 05:14:00.285514
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ribavirin Teva Pharma B.V.

[RSS](/en/individual-human-medicine.xml/66963)

##### Withdrawn

This medicine's authorisation has been withdrawn

ribavirin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Ribavirin Teva Pharma B.V.](#more-information-on-ribavirin-teva-pharma-bv-1494)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 June 2021, the European Commission withdrew the marketing authorisation for Ribavirin Teva Pharma BV (ribavirin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ribavirin Teva Pharma BV was granted marketing authorisation in the EU on 1 July 2009 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Ribavirin Teva Pharma BV is a generic medicine of Rebetol.

The European Public Assessment Report (EPAR) for Ribavirin Teva Pharma BV is updated to indicate that the marketing authorisation is no longer valid.

Ribavirin Teva Pharma B.V. : EPAR - Medicine overview

English (EN) (679.84 KB - PDF)

**First published:** 19/10/2009

**Last updated:** 09/07/2021

[View](/en/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-967)

български (BG) (774.64 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/bg/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_bg.pdf)

español (ES) (678.78 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/es/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_es.pdf)

čeština (CS) (753.87 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/cs/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_cs.pdf)

dansk (DA) (677.04 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/da/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_da.pdf)

Deutsch (DE) (680.96 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/de/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_de.pdf)

eesti keel (ET) (675.87 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/et/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_et.pdf)

ελληνικά (EL) (777.72 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/el/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_el.pdf)

français (FR) (680.07 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/fr/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_fr.pdf)

hrvatski (HR) (698.34 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/hr/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_hr.pdf)

italiano (IT) (677.05 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/it/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (752.77 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/lv/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (703.95 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/lt/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_lt.pdf)

magyar (HU) (748.39 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/hu/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_hu.pdf)

Malti (MT) (755.38 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/mt/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_mt.pdf)

Nederlands (NL) (678.78 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/nl/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_nl.pdf)

polski (PL) (753.39 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/pl/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_pl.pdf)

português (PT) (679.35 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/pt/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_pt.pdf)

română (RO) (704.5 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/ro/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_ro.pdf)

slovenčina (SK) (754.6 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sk/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_sk.pdf)

slovenščina (SL) (744.28 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sl/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_sl.pdf)

Suomi (FI) (677.36 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/fi/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_fi.pdf)

svenska (SV) (677.57 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sv/documents/overview/ribavirin-teva-pharma-bv-epar-medicine-overview_sv.pdf)

## Product information

Ribavirin Teva Pharma B.V. : EPAR - Product Information

English (EN) (2.61 MB - PDF)

**First published:** 19/10/2009

**Last updated:** 09/07/2021

[View](/en/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-530)

български (BG) (4.43 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/bg/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_bg.pdf)

español (ES) (1.9 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/es/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_es.pdf)

čeština (CS) (3.66 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/cs/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_cs.pdf)

dansk (DA) (1.82 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/da/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_da.pdf)

Deutsch (DE) (1.95 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/de/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_de.pdf)

eesti keel (ET) (1.8 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/et/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_et.pdf)

ελληνικά (EL) (4.5 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/el/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_el.pdf)

français (FR) (1.92 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/fr/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_fr.pdf)

hrvatski (HR) (2.05 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/hr/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_hr.pdf)

íslenska (IS) (1.88 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/is/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_is.pdf)

italiano (IT) (2.01 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/it/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_it.pdf)

latviešu valoda (LV) (3.59 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/lv/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.01 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/lt/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_lt.pdf)

magyar (HU) (3.85 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/hu/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_hu.pdf)

Malti (MT) (3.63 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/mt/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_mt.pdf)

Nederlands (NL) (1.87 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/nl/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_nl.pdf)

norsk (NO) (1.83 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/no/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_no.pdf)

polski (PL) (3.89 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/pl/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_pl.pdf)

português (PT) (1.9 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/pt/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_pt.pdf)

română (RO) (2.19 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/ro/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_ro.pdf)

slovenčina (SK) (3.59 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sk/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_sk.pdf)

slovenščina (SL) (3.35 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sl/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_sl.pdf)

Suomi (FI) (1.94 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/fi/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_fi.pdf)

svenska (SV) (1.72 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

09/07/2021

[View](/sv/documents/product-information/ribavirin-teva-pharma-bv-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0023 22/06/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ribavirin Teva Pharma B.V. : EPAR - All Authorised presentations

English (EN) (721.61 KB - PDF)

**First published:** 08/07/2009

**Last updated:** 09/07/2021

[View](/en/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-66)

български (BG) (814.56 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/bg/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_bg.pdf)

español (ES) (722.57 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/es/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_es.pdf)

čeština (CS) (766.74 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/cs/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (721.71 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/da/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (721.23 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/de/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (722.49 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/et/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (809.77 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/el/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_el.pdf)

français (FR) (722.58 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/fr/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (598.33 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/hr/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (599.54 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/is/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_is.pdf)

italiano (IT) (722.44 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/it/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (804.36 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/lv/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (790.1 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/lt/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (805.59 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/hu/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (803.91 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/mt/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (721.98 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/nl/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (721.44 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/no/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_no.pdf)

polski (PL) (767.98 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/pl/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_pl.pdf)

português (PT) (722.61 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/pt/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_pt.pdf)

română (RO) (786.06 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/ro/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (767.01 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/sk/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (736.98 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/sl/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (598.87 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/fi/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (721.96 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

09/07/2021

[View](/sv/documents/all-authorised-presentations/ribavirin-teva-pharma-bv-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ribavirin Teva Pharma B.V. Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP01

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).

Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/001064

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 23/04/2009 Marketing authorisation issued 01/07/2009 Withdrawal of marketing authorisation 22/06/2021 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ribavirin Teva Pharma B.V. : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (820.78 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 09/07/2021

[View](/en/documents/procedural-steps-after/ribavirin-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Ribavirin Teva Pharma B.V. : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/318726/2014

English (EN) (638.97 KB - PDF)

**First published:** 12/06/2014

**Last updated:** 09/07/2021

[View](/en/documents/scientific-conclusion/ribavirin-teva-pharma-bv-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Ribavirin Teva Pharma B.V.-H-C-1064-II-10 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/461787/2013

English (EN) (802.36 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 09/07/2021

[View](/en/documents/variation-report/ribavirin-teva-pharma-bv-h-c-1064-ii-10-epar-assessment-report-variation_en.pdf)

Ribavirin Teva Pharma B.V.-H-C-1064-A20-07 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/13297/2013

English (EN) (900.24 KB - PDF)

**First published:** 12/03/2013

**Last updated:** 09/07/2021

[View](/en/documents/variation-report/ribavirin-teva-pharma-bv-h-c-1064-a20-07-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Ribavirin Teva Pharma B.V. : EPAR - Public assessment report

English (EN) (1.02 MB - PDF)

**First published:** 27/07/2009

**Last updated:** 09/07/2021

[View](/en/documents/assessment-report/ribavirin-teva-pharma-bv-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Ribavirin Teva Pharma BV

Reference Number: EMEA/CHMP/228100/2009

English (EN) (606.02 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 09/07/2021

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ribavirin-teva-pharma-bv_en.pdf)

#### More information on Ribavirin Teva Pharma B.V.

Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility

Reference Number: EMA/796016/2012 Rev 1

English (EN) (652.34 KB - PDF)

**First published:** 14/12/2012

**Last updated:** 09/07/2021

[View](/en/documents/referral/questions-and-answers-review-medicines-which-studies-have-been-conducted-texas-based-cetero-research-facility_en.pdf)

**This page was last updated on** 09/07/2021

## Share this page

[Back to top](#main-content)